203 related articles for article (PubMed ID: 24006363)
1. Activation and control of p53 tetramerization in individual living cells.
Gaglia G; Guan Y; Shah JV; Lahav G
Proc Natl Acad Sci U S A; 2013 Sep; 110(38):15497-501. PubMed ID: 24006363
[TBL] [Abstract][Full Text] [Related]
2. Constant rate of p53 tetramerization in response to DNA damage controls the p53 response.
Gaglia G; Lahav G
Mol Syst Biol; 2014 Oct; 10(10):753. PubMed ID: 25344068
[TBL] [Abstract][Full Text] [Related]
3. Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53.
Rajagopalan S; Huang F; Fersht AR
Nucleic Acids Res; 2011 Mar; 39(6):2294-303. PubMed ID: 21097469
[TBL] [Abstract][Full Text] [Related]
4. p53 tetramerization: at the center of the dominant-negative effect of mutant p53.
Gencel-Augusto J; Lozano G
Genes Dev; 2020 Sep; 34(17-18):1128-1146. PubMed ID: 32873579
[TBL] [Abstract][Full Text] [Related]
5. p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.
Fischer NW; Prodeus A; Malkin D; Gariépy J
Cell Cycle; 2016 Dec; 15(23):3210-3219. PubMed ID: 27754743
[TBL] [Abstract][Full Text] [Related]
6. Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions.
Stavridi ES; Chehab NH; Caruso LC; Halazonetis TD
Protein Sci; 1999 Sep; 8(9):1773-9. PubMed ID: 10493578
[TBL] [Abstract][Full Text] [Related]
7. Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to DNA damage.
Choi M; Shi J; Jung SH; Chen X; Cho KH
Sci Signal; 2012 Nov; 5(251):ra83. PubMed ID: 23169817
[TBL] [Abstract][Full Text] [Related]
8. In Situ Monitoring of p53 Protein and MDM2 Protein Interaction in Single Living Cells Using Single-Molecule Fluorescence Spectroscopy.
Du Z; Yu J; Li F; Deng L; Wu F; Huang X; Bergstrand J; Widengren J; Dong C; Ren J
Anal Chem; 2018 May; 90(10):6144-6151. PubMed ID: 29671327
[TBL] [Abstract][Full Text] [Related]
9. Ultraslow oligomerization equilibria of p53 and its implications.
Natan E; Hirschberg D; Morgner N; Robinson CV; Fersht AR
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14327-32. PubMed ID: 19667193
[TBL] [Abstract][Full Text] [Related]
10. p53 domains: structure, oligomerization, and transformation.
Wang P; Reed M; Wang Y; Mayr G; Stenger JE; Anderson ME; Schwedes JF; Tegtmeyer P
Mol Cell Biol; 1994 Aug; 14(8):5182-91. PubMed ID: 8035799
[TBL] [Abstract][Full Text] [Related]
11. Conformational detection of p53's oligomeric state by FlAsH Fluorescence.
Webber TM; Allen AC; Ma WK; Molloy RG; Kettelkamp CN; Dow CA; Gage MJ
Biochem Biophys Res Commun; 2009 Jun; 384(1):66-70. PubMed ID: 19393630
[TBL] [Abstract][Full Text] [Related]
12. p53 Dimers associate with a head-to-tail response element to repress cyclin B transcription.
Lipski R; Lippincott DJ; Durden BC; Kaplan AR; Keiser HE; Park JH; Levesque AA
PLoS One; 2012; 7(8):e42615. PubMed ID: 22905155
[TBL] [Abstract][Full Text] [Related]
13. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization.
Shieh SY; Taya Y; Prives C
EMBO J; 1999 Apr; 18(7):1815-23. PubMed ID: 10202145
[TBL] [Abstract][Full Text] [Related]
14. Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line.
Ochiai K; Azakami D; Morimatsu M; Hirama H; Kawakami S; Nakagawa T; Michishita M; Egusa AS; Sasaki T; Watanabe M; Omi T
Oncol Rep; 2018 Jul; 40(1):488-494. PubMed ID: 29750295
[TBL] [Abstract][Full Text] [Related]
15. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
16. Stability of p53 oligomers: Tetramerization of p53 impinges on its stability.
Luwang JW; Nair AR; Natesh R
Biochimie; 2021 Oct; 189():99-107. PubMed ID: 34197865
[TBL] [Abstract][Full Text] [Related]
17. Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization.
Hanson S; Kim E; Deppert W
Oncogene; 2005 Feb; 24(9):1641-7. PubMed ID: 15674341
[TBL] [Abstract][Full Text] [Related]
18. Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.
Okal A; Cornillie S; Matissek SJ; Matissek KJ; Cheatham TE; Lim CS
Mol Pharm; 2014 Jul; 11(7):2442-52. PubMed ID: 24836513
[TBL] [Abstract][Full Text] [Related]
19. Mathematical Modeling of p53 Pathways.
Kim E; Kim JY; Lee JY
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635420
[TBL] [Abstract][Full Text] [Related]
20. The role of tetramerization in p53 function.
Chène P
Oncogene; 2001 May; 20(21):2611-7. PubMed ID: 11420672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
